Evaluation of prognostic factors in AML

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 4, 2011, Pages 485-488

  Rowe, Jacob M ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Acute Leukemia Forum; acute myeloid leukemia; AML; AML biology; cytogenetics; genetics; karyotype; molecular; prognosis; survival; therapy

Indexed keywords

ANTHRACYCLINE; CD135 ANTIGEN; CYTARABINE; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; EVALUATION; GENE INTERACTION; GENE MUTATION; HUMAN; LOW DRUG DOSE; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 82355170638     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.09.003     Document Type: Editorial

References (15)

1. T.J. Ley, L. Ding, and M.J. Walter DNMT3A mutations in acute myeloid leukemia N Engl J Med 363 2010 2424 2433
2. A.M. Melnick Epigenetics in AML Best Pract Res Clin Haematol 23 2010 463 468
3. E. Taskesen, L. Bullinger, and A. Corbacioglu Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity Blood 117 2011 2469 2475
4. J.M. Rowe The evolving paradigm of prognostic factors in AML: introduction to the Acute Leukemia Forum 2010 Best Pract Res Clin Haematol 23 2010 453 456
5. J.M. Rowe, and M.S. Tallman How I treat acute myeloid leukemia Blood 116 2010 3147 3156
6. J.O. Moore, S.L. George, and R.K. Dodge Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427 (Pubitemid 40628181)
7. A.K. Burnett, R.K. Hills, and D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
8. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
9. T. Buchner, W.E. Berdel, and C. Haferlach Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group J Clin Oncol 27 2009 61 69
10. S. Petersdorf, K. Kopecky, and R.K. Stuart Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia Blood 114 2009 326 abstr 790
11. H.P. Erba Has there been progress in the treatment of older patients with acute myeloid leukemia? Best Pract Res Clin Haematol 23 2010 495 501
12. M.S. Tallman, D.G. Gilliland, and J.M. Rowe Drug therapy for acute myeloid leukemia Blood 106 2005 1154 1163 (Pubitemid 41130866)
13. C.D. Bloomfield, D. Lawrence, and J.C. Byrd Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 58 1998 4173 4179 (Pubitemid 28440576)
14. A.K. Burnett, D. Milligan, and A.G. Prentice A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 109 2007 1114 1124 (Pubitemid 46435390)
15. R.C. Gallo Research and discovery of the first human cancer virus, HTLV-1 Best Pract Res Clin Haematol 24 2011 559 565